Flu Virus Protein NS2 Sabotages Interferon Alarm by Hijacking Host Ubiquitin Regulator UBL7

Influenza A virus remains one of the most formidable human pathogens, capable of sweeping through populations in seasonal waves and occasional pandemics. A central reason for its success lies in its ability to blunt the body’s earliest antiviral defenses, particularly the type I interferon system that normally rings the alarm bell within hours of infection. A new study published in Virology Journal by Xiaotian Yang, Junnan Shi, Xinyu Li and colleagues, led by corresponding authors Ruixue Xia, Wei Jiang and Min Fang, has now uncovered a previously unrecognized trick that the virus uses to silence this alarm. The research shows that the viral nonstructural protein 2, better known as NS2, actively suppresses type I interferon signaling by competing with a key host adaptor protein for access to a small ubiquitin-like regulator called UBL7.

The type I interferon response is the cornerstone of innate antiviral immunity. When sensor proteins inside the cell detect viral RNA, they pass the signal along a molecular relay that converges on MAVS, the mitochondrial antiviral signaling protein, which sits on the outer membrane of mitochondria and related organelles. Once activated, MAVS recruits downstream signaling complexes that ultimately switch on transcription factors responsible for driving the production of interferon and inflammatory cytokines. These molecules then spread to neighboring cells, placing them into an antiviral state that makes replication of the virus far more difficult. Because this pathway is so potent, influenza A virus has evolved multiple proteins dedicated to interfering with it at different points, and mapping these interference strategies is essential for understanding viral pathogenesis.

NS2, also referred to in the literature as NEP, has traditionally been viewed as a logistics protein rather than an immune antagonist. It is a component of the viral particle and its best-characterized job is the nuclear export of viral ribonucleoprotein complexes, the vRNPs, which must travel from the nucleus, where the viral genome is transcribed and replicated, to the cytoplasm, where new virions are assembled. The new study, however, demonstrates that this protein has a second, hidden function. The authors report that NS2 suppresses type I interferon responses by physically interacting with UBL7, a ubiquitin-like protein also known as BMSC-UbP, which the study identifies as a positive regulator of interferon signaling that promotes K27-linked polyubiquitination of MAVS.

Ubiquitination is a versatile chemical modification in which ubiquitin molecules are attached to target proteins, and the way those ubiquitin chains are linked determines the biological outcome. K27-linked polyubiquitination of MAVS serves as a molecular scaffold signal that helps assemble the downstream activation complexes needed for robust interferon induction. UBL7 supports this process, acting as an enabler of MAVS activation. The new work shows that NS2 interferes with this enabling role. By binding to UBL7, the viral protein reduces the K27-linked polyubiquitination of MAVS and thereby hinders the productive interaction between UBL7 and MAVS. The consequence is a dampened activation of the entire interferon signaling cascade, giving the virus a wider window in which to replicate before the antiviral state takes hold.

The experimental logic behind this conclusion rested on a series of complementary approaches. The researchers examined the interaction between NS2 and UBL7 and demonstrated that this interaction competes with the association of UBL7 with MAVS. In effect, NS2 acts as a molecular decoy, sequestering UBL7 away from its legitimate partner on the mitochondrial membrane. This competitive mechanism is elegant in its simplicity: rather than degrading UBL7 or MAVS, the virus merely occupies a binding surface, diverting a host cofactor from its antiviral duty. Such competitive inhibition strategies are a recurring theme in viral immune evasion, and the identification of UBL7 as a target adds a new node to the map of host factors that influenza exploits or subverts.

To confirm that the effect observed in isolated protein interaction assays was meaningful during genuine infection, the team turned to cellular models of influenza infection using the PR8 strain, an H1N1 influenza A virus. When NS2 was knocked down during infection, cells that overexpressed UBL7 showed enhanced type I interferon signaling, indicating that removing the viral protein allowed the host cofactor to resume its stimulatory role. The same enhancement was seen in wild-type mouse embryonic fibroblasts, a standard laboratory cell type for innate immunity studies. Crucially, however, the enhancement disappeared in mouse embryonic fibroblasts in which the UBL7 gene had been knocked out. This genetic dependency is the strongest form of evidence that UBL7 is the relevant target: if NS2’s suppressive effect requires the presence of UBL7, then UBL7 must be the mediator through which NS2 exerts its inhibitory influence on interferon signaling.

The findings carry several implications for virology and immunology. First, they assign a novel immune evasion function to a viral protein whose role in antiviral immune evasion had been poorly understood. NS2 now joins the growing roster of influenza A virus proteins, including NS1, PB1-F2 and others, that contribute to the virus’s arsenal against innate immunity. Second, the study elevates UBL7 from a relatively obscure ubiquitin-like protein to a defined positive regulator of MAVS signaling, clarifying its position in the antiviral pathway and suggesting that other viruses may target it as well. Third, the work illustrates how a single viral protein can be multifunctional, combining a structural logistics role in the viral life cycle with an immunomodulatory role, a design principle that allows influenza to pack considerable functionality into a compact genome of only eight RNA segments.

From a broader perspective, the study deepens understanding of the interplay between influenza A virus and the host innate immune response, an arms race that has shaped both viral evolution and human susceptibility to disease. Every immune evasion mechanism the virus possesses represents a potential vulnerability that antiviral therapies could exploit. If the NS2-UBL7 interaction is required for efficient viral replication in the face of the interferon response, then molecules designed to block that interaction, or to stabilize the UBL7-MAVS axis, could theoretically restore a stronger early antiviral response in infected cells. The authors’ identification of the mechanistic interface, namely the competition between NS2 and MAVS for UBL7 binding, provides a concrete molecular target for such future exploration, although the current study is a basic research advance rather than a therapeutic development.

The research was conducted by teams based at the School of Life Sciences of Henan University in Kaifeng and the Henan Key Laboratory of Synthetic Biology and Biomanufacturing, together with collaborators at the CAS Key Laboratory of Pathogenic Microbiology and Immunology at the Institute of Microbiology, Chinese Academy of Sciences in Beijing. Xiaotian Yang, Junnan Shi and Xinyu Li contributed equally to the work, with Min Fang serving as senior corresponding author alongside Ruixue Xia and Wei Jiang. The project received sponsorship from the Natural Science Foundation of Henan Province and the National Natural Science Foundation of China, and the animal experimental protocol was approved by the Biomedical Research Ethics Committee of Henan University. The article is published open access under a Creative Commons Attribution 4.0 license, and the version shared in early access is citable with a permanent digital object identifier.

Taken together, the study delivers a clear mechanistic story: influenza A virus NS2 binds UBL7, competes with MAVS for that interaction, reduces K27-linked polyubiquitination of MAVS, and thereby suppresses type I interferon signaling, with the genetic knockout experiments confirming that none of this happens without UBL7 present. These findings provide new insights into how influenza disarms innate immunity and expand the catalog of host factors that the virus manipulates. As researchers continue to chart the full network of viral-host interactions, discoveries of this kind not only explain how the virus evades detection but also illuminate the normal wiring of the interferon pathway itself, knowledge that may ultimately inform the design of vaccines and antivirals aimed at tipping the balance back in favor of the host.

Subject of Research: Influenza A virus NS2-mediated inhibition of type I interferon signaling through UBL7 and MAVS

Article Title: Influenza A virus nonstructural protein 2 inhibits IFN-I signaling via competing with MAVS to bind to UBL7

Article References: Yang, X., Shi, J., Li, X., Chen, Y., Bi, K., Ji, W., Lu, Q., Song, X., Jiang, Z., Xu, H., Gu, X., Xia, R., Jiang, W., & Fang, M. (2026). Influenza A virus nonstructural protein 2 inhibits IFN-I signaling via competing with MAVS to bind to UBL7. Virology Journal. https://doi.org/10.1186/s12985-026-03316-w

Image Credits: AI Generated

DOI: 10.1186/s12985-026-03316-w

Keywords: influenza A virus, NS2 protein, UBL7, MAVS, type I interferon, innate immunity, immune evasion, K27-linked polyubiquitination, viral proteins, antiviral signaling, H1N1, virology